RBC Capital initiated coverage of Neumora Therapeutics with an Outperform rating and $24 price target. The analyst expects the meaningful, statistically significant mood improvements and “differentiated” safety profile for the company’s KOR antagonist navacaprant to translate to Phase III and commercial success in major depressive disorder. The firm says the shares are undervaluing Neumora as a potential next-generation neuroscience leader.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NMRA: